# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Atai Life Sciences' BPL-003 shows strong Phase 2b results for treatment-resistant depression, with potential $2.5 billion s...
Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.
FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the thera...
Retail investors are preparing for the kick-off of the Q3 earnings season, with big banks and other top stocks reporting this w...
https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-approves-labeling-changes-include-boxed-warning-...
Johnson & Johnson (NYSE:JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LL...
Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Equal-Weight and raises the price tar...
Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug po...